InMed Pharmaceuticals (INM) Net Cash Flow Growth (3y) (2022 - 2026)
InMed Pharmaceuticals (INM) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -62.71% |
| 10 | InMed Pharmaceuticals | 7.08 Mn | 1.84 Mn | - | 7.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.49% |
| Dec 31, 2025 | -42.82% |
| Sep 30, 2025 | -36.62% |
| Jun 30, 2025 | 184.23% |
| Mar 31, 2025 | 30.73% |
| Dec 31, 2024 | 18.95% |
| Sep 30, 2024 | -28.54% |
| Jun 30, 2024 | 21.03% |
| Mar 31, 2024 | -50.56% |
| Dec 31, 2023 | -33.11% |
| Sep 30, 2023 | -14.82% |
| Jun 30, 2023 | 20.91% |
| Mar 31, 2023 | -6.51% |
| Dec 31, 2022 | 48.56% |
| Sep 30, 2022 | 32.04% |